{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:11Z","timestamp":1787987891882,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Center for Advancing Translational Science (NCATS) Einstein \u2013 Montefiore CTSA","award":["KL2 TR002558"],"award-info":[{"award-number":["KL2 TR002558"]}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"crossref","award":["917144"],"award-info":[{"award-number":["917144"]}],"id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institutes of Health NIH\/NIAMS","award":["K23 AR068441"],"award-info":[{"award-number":["K23 AR068441"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04108-0","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T23:33:46Z","timestamp":1744414426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Factors associated with worsening interstitial fibrosis\/tubular atrophy in lupus nephritis patients undergoing clinically indicated repeat kidney biopsy"],"prefix":"10.1186","volume":"26","author":[{"given":"Daming","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra Londo\u00f1o","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Salgado","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"6","key":"4108_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"JD Fitzgerald","year":"2012","unstructured":"Hahn B, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797\u2013808.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"4108_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521\u201330.","journal-title":"Kidney Int"},{"issue":"4","key":"4108_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, et al. Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National institutes of health activity and chronicity indices. Kidney Int. 2018;93(4):789\u201396.","journal-title":"Kidney Int"},{"key":"4108_CR4","doi-asserted-by":"crossref","unstructured":"Hsieh C, et al. Tubulointerstitial inflammation and scarring predict outcome in lupus nephritis. Arthritis care & research; 2011;63(6):865.","DOI":"10.1002\/acr.20441"},{"key":"4108_CR5","doi-asserted-by":"crossref","unstructured":"Leatherwood C, et al. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Seminars in arthritis and rheumatism. Elsevier. 2019.","DOI":"10.1016\/j.semarthrit.2019.06.002"},{"issue":"9","key":"4108_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/ki.2010.13","volume":"77","author":"F Yu","year":"2010","unstructured":"Yu F, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney Int. 2010;77(9):820\u20139.","journal-title":"Kidney Int"},{"issue":"2","key":"4108_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/ckj\/sfx093","volume":"11","author":"PC Wilson","year":"2018","unstructured":"Wilson PC, Kashgarian M, Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney J. 2018;11(2):207\u201318.","journal-title":"Clin Kidney J"},{"issue":"1","key":"4108_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nep.12555","volume":"21","author":"F Pagni","year":"2016","unstructured":"Pagni F, et al. Tubulointerstitial lesions in lupus nephritis: international multicentre study in a large cohort of patients with repeat biopsy. Nephrology. 2016;21(1):35\u201345.","journal-title":"Nephrology"},{"issue":"2","key":"4108_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.55563\/clinexprheumatol\/ztb9sx","volume":"38","author":"OC Kwon","year":"2019","unstructured":"Kwon OC, et al. Factors associated with aggravation of tubulointerstitial damage on repeated biopsies in lupus nephritis patients with treatment failure. Clin Exp Rheumatol. 2019;38(2):239\u201344.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"4108_CR10","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1093\/ndt\/gft272","volume":"28","author":"F Pagni","year":"2013","unstructured":"Pagni F, et al. The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. Nephrol Dial Transpl. 2013;28(12):3014\u201323.","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"4108_CR11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","volume":"32","author":"A Malvar","year":"2017","unstructured":"Malvar A, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dialysis Transplantation. 2017;32(8):1338\u201344.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"4","key":"4108_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","volume":"94","author":"M De Rosa","year":"2018","unstructured":"De Rosa M, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788\u201394.","journal-title":"Kidney Int"},{"issue":"11","key":"4108_CR13","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","volume":"59","author":"I Parodis","year":"2020","unstructured":"Parodis I, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology. 2020;59(11):3424\u201334.","journal-title":"Rheumatology"},{"issue":"1","key":"4108_CR14","doi-asserted-by":"publisher","first-page":"e000018","DOI":"10.1136\/lupus-2014-000018","volume":"1","author":"A Zickert","year":"2014","unstructured":"Zickert A, et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1(1):e000018.","journal-title":"Lupus Sci Med"},{"issue":"4","key":"4108_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/clinchem\/hvab278","volume":"68","author":"WG Miller","year":"2022","unstructured":"Miller WG, et al. National kidney foundation laboratory engagement working group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: practical guidance for clinical laboratories. Clin Chem. 2022;68(4):511\u201320.","journal-title":"Clin Chem"},{"key":"4108_CR16","doi-asserted-by":"crossref","unstructured":"Broder A, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: a retrospective cohort study. Seminars in arthritis and rheumatism. Elsevier 2018.","DOI":"10.1016\/j.semarthrit.2017.07.007"},{"issue":"suppl1","key":"4108_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ndt\/13.suppl_1.80","volume":"13","author":"G D\u2019Amico","year":"1998","unstructured":"D\u2019Amico G. Tubulo-interstitial damage in glomerular diseases: its role in the progression of the renal damage. Nephrol dialysis Transplantation: Official Publication Eur Dialysis Transpl Association-European Ren Association. 1998;13(suppl1):80\u20135.","journal-title":"Nephrol dialysis Transplantation: Official Publication Eur Dialysis Transpl Association-European Ren Association"},{"key":"4108_CR18","doi-asserted-by":"crossref","unstructured":"Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Seminars in nephrology. Elsevier 2015.","DOI":"10.1016\/j.semnephrol.2015.08.007"},{"issue":"1","key":"4108_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","volume":"97","author":"A Malvar","year":"2020","unstructured":"Malvar A, et al. Kidney biopsy\u2013based management of maintenance immunosuppression is safe and May ameliorate flare rate in lupus nephritis. Kidney Int. 2020;97(1):156\u201362.","journal-title":"Kidney Int"},{"key":"4108_CR20","doi-asserted-by":"crossref","unstructured":"Malvar A et al. Remission of lupus nephritis: the trajectory of histological response in successfully treated patients. Lupus Sci Med. 2023:10(1).","DOI":"10.1136\/lupus-2023-000932"},{"issue":"11","key":"4108_CR21","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1093\/ckj\/sfac150","volume":"15","author":"GM Lledo-Ibanez","year":"2022","unstructured":"Lledo-Ibanez GM, et al. Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment. Clin Kidney J. 2022;15(11):2081\u20138.","journal-title":"Clin Kidney J"},{"key":"4108_CR22","doi-asserted-by":"crossref","unstructured":"Sciascia S et al. Renal fibrosis in lupus nephritis. Int J Mol Sci. 2022. 23(22).","DOI":"10.3390\/ijms232214317"},{"issue":"1","key":"4108_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","volume":"162","author":"Z Liu","year":"2015","unstructured":"Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18\u201326.","journal-title":"Ann Intern Med"},{"issue":"3","key":"4108_CR24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","volume":"70","author":"SC Palmer","year":"2017","unstructured":"Palmer SC, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: A network Meta-analysis of randomized trials. Am J Kidney Dis. 2017;70(3):324\u201336.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4108_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4108_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, et al. Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u201328.","journal-title":"N Engl J Med"},{"issue":"10289","key":"4108_CR27","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070\u201380.","journal-title":"Lancet"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04108-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04108-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04108-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:01:27Z","timestamp":1744477287000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04108-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4108"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04108-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3867933\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the Albert Einstein College of Medicine Institutional Review Board. Given the patients or the public were not directly involved in the design, conduct, reporting, or dissemination plans of our research, informed consent was waived by Albert Einstein College of Medicine Institutional Review Board. To ensure patient confidentiality and data security, all patient data were anonymized prior to analysis, with unique identifiers replacing any personally identifiable information. Access to the data was restricted to authorized personnel who were adherent to institutional and national guidelines for data protection Additionally, all researchers involved in the study completed training on data privacy and security protocols to further safeguard patient information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}